FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after Neoadjuvant Therapy in Adult Primary Bone Sarcomas by Benz, Matthias R. et al.
Hindawi Publishing Corporation
Sarcoma
Volume 2010, Article ID 143540, 7 pages
doi:10.1155/2010/143540
Clinical Study
FDG-PET/CT ImagingPredicts Histopathologic
TreatmentResponsesafter Neoadjuvant Therapy in
AdultPrimary Bone Sarcomas
Matthias R. Benz,1 Johannes Czernin,1 William D. Tap,2 Jeffrey J. Eckardt,3
LeanneL.Seeger,4 Martin S. Allen-Auerbach,1 SarahM.Dry,5 MichaelE.Phelps,1
Wolfgang A. Weber,6 andFritz C. Eilber1,7
1Ahmanson Biological Imaging Division, Department of Molecular and Medical Pharmacology, David Geﬀen School of Medicine,
University of California Los Angeles, Los Angeles, CA 90095-1782, USA
2Division of Medical Oncology, David Geﬀen School of Medicine, University of California Los Angeles, Los Angeles,
CA 90095-1782, USA
3Department of Orthopedic Oncology, David Geﬀen School of Medicine, University of California Los Angeles, Los Angeles,
CA 90095-1782, USA
4Department of Radiology, David Geﬀen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095-1782, USA
5Department of Pathology, David Geﬀen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095-1782, USA
6Abteilung Nuklearmedizin, University of Freiburg, 79106 Freiburg, Germany
7Division of Surgical Oncology, David Geﬀen School of Medicine, University of California Los Angeles, Los Angeles,
CA 90095-1782, USA
Correspondence should be addressed to Johannes Czernin, jczernin@mednet.ucla.edu
Received 2 September 2009; Revised 18 December 2009; Accepted 8 February 2010
Academic Editor: Marcus Schlemmer
Copyright © 2010 Matthias R. Benz et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Purpose. The aim of this study was to prospectively evaluate whether FDG-PET allows an accurate assessment of histopathologic
response to neoadjuvant treatment in adult patients with primary bone sarcomas. Methods. Twelve consecutive patients with
resectable, primary high grade bone sarcomas were enrolled prospectively. FDG-PET/CT imaging was performed prior to the
initiation and after completion of neoadjuvant treatment. Imaging ﬁndings were correlated with histopathologic response. Results.
Histopathologic responders showed signiﬁcantly more pronounced decreases in tumor FDG-SUVmax from baseline to late follow
up than non-responders (64±19% versus 29±30%, resp.; P = .03). Using a 60% decrease in tumor FDG-uptake as a threshold for
metabolic response correctly classiﬁed 3 of 4 histopathologic responders and 7 of 8 histopathologic non-responders as metabolic
responders and non-responders, respectively (sensitivity, 75%; speciﬁcity, 88%). Conclusion. These results suggest that changes in
FDG-SUVmax at the end of neoadjuvant treatment can identify histopathologic responders and non-responders in adult primary
bone sarcoma patients.
1.Introduction
Positron emission tomography (PET) with the glucose
analog [ 18F]ﬂuorodeoxyglucose (18F-FDG) can be used
to diagnose [1], grade [2], stage [3, 4], and to assess
treatment response [5–7] in soft tissue and bone sarcomas.
We have recently reported that treatment monitoring with
FDG-PET in patients with soft tissue sarcoma provides
accurate response information (as determined by %-necrosis
in excised tumors) after the initial cycle [5]a n da f t e r
completion [8] of neoadjuvant therapy when thresholds of
35% and 60% reductions in tumor FDG SUV were applied.
Histopathologic response to neoadjuvant therapy is a
well established and signiﬁcant prognostic factor for disease-
free and overall survival in patients with bone sarcomas
[9, 10]. Bone sarcomas tend to have higher response2 Sarcoma
rates to neoadjuvant treatment than soft tissue sarcomas
with 5-year disease-free survival rates of 60%–75% [11].
In agreement with previous observations in patients with
soft tissue sarcomas [8], a study in bone sarcomas has
suggested that a reduction of tumor metabolic activity
by more than 60% at the end of treatment accurately
predicts histopathologic tumor response [7]. For the current
study we tested whether applying this threshold of 60%
reduction in tumor FDG SUVmax after completion of
therapy in a prospectively enrolled study group yielded
reliablehistopathologic responsepredictions inpatients with
bone sarcomas.
2.MaterialandMethods
2.1. Patients and Study Design. From February 2005 to
November 2007, twelve adult patients with resectable high-
grade bone sarcomas were prospectively enrolled in this
study. Participants underwent a pretreatment (baseline)
PET/CT scan and a followup scan after the completion of
neoadjuvant therapy. The study population consisted of 7
females and 5 males with a mean age of 31.6 ± 15.0 years
(range, 18–61 years). All patients presented with primary,
nonmetastatic disease at the time of the ﬁrst PET/CT scan.
The study group consisted of six patients with osteosar-
coma (50%), 3 with Ewing’s sarcoma (25%), 2 with dedif-
ferentiated chondrosarcoma (17%), and 1 with a malignant
giant cell tumor of the bone (8%).
A baseline FDG-PET/CT scan was performed prior to
the initiation of neoadjuvant therapy after a mean interval of
6.1±5.2days(range,1–15).Afollowupscanaftercompletion
of neoadjuvant treatment was performed in all patients after
a mean interval of 15.3±7.6 days (range, 3–24 days) prior to
surgical resection. The study design is depicted in Figure 1.
All participants gave written informed consent after the
details of the study were explained by a study physician.
The study was approved by the UCLA Institutional Review
Board.
2.2. Neoadjuvant Therapy. The neoadjuvant treatments var-
ied with the bone sarcoma subtype. Patients with Ewing’s
sarcoma were treated with alternating cycles of VAC (vin-
cristine, adriamycin, cytoxan) and IE (ifosfamide, etopo-
side) [11]. Patients underwent 4 cycles (2 VAC and 2
IE) prior to surgical resection. Patients with osteosar-
coma underwent treatment protocols that utilized a 3-
drug regimen in the neoadjuvant setting. This consisted
of two cycles of chemotherapy. Each cycle consisted of
doxorubicin (75mg/m2) and cisplatin (100mg/m2) followed
by two doses of high-dose methotrexate (12grams/m2)
with leucovorin rescue. If age or performance status
prevented the use of methotrexate, two cycles of dox-
orubicin and cisplatin were given prior to resection.
Patients with the malignant giant cell tumor and the
dediﬀerentiated chondrosarcomas received ifosfamide and
doxorubicin-based chemotherapy. Five of 12 patients (42%)
received additional neoadjuvant external beam radia-
tion.
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Figure 1: Study design.
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Figure 2: Changes in SUVmax from baseline to late followup are
signiﬁcantly correlated with percent of histopathologic necrosis
in the excised tumor tissue (Pearson Correlation Coeﬃcient =
−0.75;P = .005).
2.3. PET/CT Image Acquisition and Reconstruction. PET/CT
studies were performed using a hybrid device consisting of a
PET scanner with LSO detectors (ECAT ACCEL) and a dual
detector helical CT scanner (Siemens Biograph Duo PET/CT
scanner).
To standardize imaging conditions and to assure that
elevated blood glucose levels would not aﬀect FDG uptake
measurements, patients were instructed to fast for at least
6 hours prior to FDG-PET/CT imaging. Blood glucose was
measured before the injection of FDG (mean: 96±16mg/dL;
range: 78–141mg/dL).
The CT acquisition parameters were: 130kVp, 120mAs,
1 second rotation, and 4 mm slice collimation, 8-mm/s bed
speed. The CT portion of the study was performed with
the administration of intra-venous contrast (Omnipaque,
Novaplus) in 11 patients at baseline and 8 patients at
followup. In addition, 12 patients received oral contrast at
baseline and 11 patients at followup, respectively.
Approximately sixty minutes before image acquisition
patients were injected intravenously with 0.21mCi/kg of 18F-
FDG. Depending on the patient’s body weight PET emission
scandurationperbedpositionvariedbetween1to5minutes
as previously described [12, 13]. Care was taken to assure a
similar time interval from injection of FDG to the start of
imaging for baseline and followup studies.
T h eC Ti m a g e sw e r er e c o n s t r u c t e du s i n gc o n v e n t i o n a l
ﬁltered back-projection, at 3.4 mm axial intervals to match
the slice separation of the PET data.
PETimageswerereconstructedusingiterativealgorithms
(OSEM two iterations, eight subsets). To correct for photonSarcoma 3
attenuation a previously published CT-based algorithm was
applied [14].
2.4.ImageAnalysis. TheMiradaworkstation(REVEALMVS;
CTI Mirada Solutions) was used to view PET and CT
images and to measure tumor FDG uptake. All FDG
images were analyzed by one observer who was blinded to
histopathologic treatment response. The single maximum
pixel value within the slice with the highest radioactivity
concentration was detected on baseline and followup scans
as previously described [15]. The maximum standardized
uptake value (SUVmax) was calculated by dividing the
activity in that pixel by the administered dose normalized
to patient body weight (g/mL). One radiologist blinded to
PET and histopathological response data measured tumor
diameters on baseline and followup CT images.
2.5. Metabolic Response Criteria. As previously reported, a
r e d u c t i o ni nt u m o rS U Vb y≥60% after the course of
neoadjuvant treatment accurately predicts histopathologic
tumor response in sarcomas [7, 8]. We therefore applied this
threshold prospectively in the current study population.
2.6. Reference Standard. Following excision, a complete
cross section of tumor was submitted in multiple cassettes
for histopathologic evaluation. The fraction of tissue with
treatment eﬀect (necrosis and/or ﬁbrosis) of the total
tumor tissue served as reference standard. This is based on
previous studies demonstrating that >90% treatment eﬀect
in excised tissue after neoadjuvant treatment is associated
with favorable survival in bone sarcoma patients [9, 10].
2.7. Histopathology. Each sarcoma subtype showed charac-
teristic histopathologic features, as described in standard
texts.Pathologicdiagnosesweremadebyapathologist(S.D.)
withexpertise in sarcomapathology whowas blinded to PET
data. Osteosarcomas consisted of malignant osteoblasts with
associated malignant osteoid formation. Ewing’s sarcomas
showed sheets of small round blue cells with scant cytoplasm
and strong CD99 membrane positivity. Dediﬀerentiated
chondrosarcomas showed a biphasic pattern with foci
of hyaline cartilage, with scattered atypical chondrocytes,
admixed with a nonchondroid high-grade sarcoma. The
malignant giant cell tumor showed a mixture of giant cells
with pleomorphic nuclei and atypical mitoses and admixed
ovoid stromal cells also with atypical nuclei and mitoses; an
extensive panel of immunohistochemical stains in this case
was all negative. A complete cross section of each resected
tumor was submitted in multiple cassettes. Treatment eﬀect,
indicated by tumor necrosis and ﬁbrosis, was evaluated in
each case.
2.8. Statistical Analysis. Quantitative data are presented as
mean ± SD, median, and range. The Mann-Whitney test
and the Wilcoxon signed rank test were used for unpaired
and paired comparisons between quantitative parameters.
The Pearson correlation was performed to correlate changes
in SUVmax with percent of histopathologic necrosis in the
excised tumor. P values <. 05 were considered statistically
signiﬁcant except for the bivariate correlation (correlation
is signiﬁcant at the 0.01 level). Statistical analyses were per-
formedusingSPSSsoftwareforWindows(version14.0,SPSS
Inc., Chicago, USA) and Statistica software for Windows
(version V8.0StatSoft, Inc., Tulsa, USA).
3. Results
3.1. Changes in Tumor Diameter. Baseline and followup CT
tumor size measurements are listed in Table 1.
Mean tumor size at baseline averaged 11.7 ± 5.1cm
(median, 10.1cm; range, 6.5–22.1cm) and 11.3 ± 4.9cm
(median,9.5cm;range,6.5–21.8cm)atfollowup.Tumorsize
did not change signiﬁcantly during the course of treatment
(P = .37).
3.2. Histopathologic Response. T h en e c r o t i cf r a c t i o no ft h e
tumors averaged 61 ± 31% of the entire tumor volume
(median, 70%, range, 10%–99%). Four of 12 patients
(2 Ewing’s sarcomas, 2 Osteosarcomas) exhibited ≥90%
treatment eﬀect in the resected specimen and were therefore
classiﬁed as histopathologic responders (33% response rate).
Five patients (42%) exhibited ≤50%, and 3 patients (25%)
b e t w e e n5 0a n d9 0 %t r e a t m e n te ﬀect after neoadjuvant
therapy. These patients were classiﬁed as histopathologic
nonresponders.
3.3. Changes in Tumor Size and Histopathologic Response.
Tumor size changes in response to treatment were small
and did not diﬀer signiﬁcantly among histopathologic
responders (n = 4) and nonresponders (n = 8) (−1 ± 4%
versus 4 ± 9%; P = .16) (Figure 3).
3.4. Changes in Tumor FDG Uptake. Baseline and followup
SUVmax measurements are listed in Table 1. SUVmax
decreased by 40 ± 31% from 8.1 ± 4.1g/mL at baseline to
4.5 ± 2.7g/mL at late followup (P = .006). Tumor SUVmax
and changes in SUVmax did not diﬀer signiﬁcantly among
the sarcoma subtypes (P = NS).
3.5. Changes in FDG Uptake and Histopathologic Response.
Histopathologic responders showed signiﬁcantly more pro-
nounced decreases in tumor FDG uptake from baseline to
late followup compared to nonresponders (64 ± 19% versus
29 ± 30%; P = .03). C h a n g e si nS U V m a xi nr e s p o n s et o
treatment were signiﬁcantly correlated with percent necrosis
in the excised tumor (Pearson Correlation Coeﬃcient =
−0.75; P = .005; Figure 2).
A 60% decrease in SUVmax from baseline to late
followup as threshold criterion correctly classiﬁed 3 of 4
histopathologic responders as metabolic responders (sensi-
tivity, 75%) and 7 of 8 histopathologic nonresponders as
metabolic nonresponders (speciﬁcity, 88%).
A single histopathologic responder and one histopatho-
logic nonresponder were misclassiﬁed as metabolic nonre-
sponder and responder, respectively (Figure 3; Table 2).4 Sarcoma
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Figure 3: (a) SUVmax values (numerical) and changes in SUVmax (bars) after completion of neoadjuvant treatment for each patient.
(b) depicts changes in tumor size from baseline to end of treatment. Histopathologic responders are illustrated in orange. Three of four
histopathologic responders showed decreases in SUVmax by ≥60% from baseline to followup scan. One histopathologic responder with a
38% decrease in FDG uptake from baseline to followup showed an SUVmax value after completion of neoadjuvant therapy of <2.5 and was
therefore correctly classiﬁed. Size changes in response to treatment were marginal.
Table 1: Patient characteristics and imaging ﬁndings.
n Subtypes Location Age Sex
Baseline End of treatment Metabolic response
(decrease ≥60%) Necrosis
SUVmax Size SUVmax Size
1 Ewing’s Sarcoma∗ Femur 22 M 12.2 22.1 2.0 21.8 Yes 99
2 Ewing’s Sarcoma∗ Fibula 19 F 4.7 7.8 1.7 7.8 Yes 90
3 Osteosarcoma Fibula 23 M 3.6 6.8 2.3 6.5 No 90
4 Osteosarcoma Tibia 58 M 9.7 8.5 2.9 8.8 Yes 90
5 Ewing’s Sarcoma∗ Femur 29 M 6.8 17.3 2.7 17.3 Yes 80
6 Osteosarcoma Femur 31 F 10.8 15.0 6.7 15.3 No 70
7 Osteosarcoma Tibia 18 F 3.9 11.2 2.4 11.9 No 70
8 Giant Cell Tumor∗ Iliac Wing 44 F 6.4 9.3 4.0 10.5 No 50
9 Osteosarcoma Femur 32 F 5.0 6.5 4.8 6.8 No 30
10 Chondrosarcoma∗ Humerus 61 M 15.7 17.4 10.6 # No 30
11 Chondrosarcoma Sternum 19 F 13.5 10.9 6.3 9.5 No 20
12 Osteosarcoma Tibia 23 F 5.3 7.1 7.0 8.2 No 10
∗Patients received additional radiation therapy; # not measurable due to obliquity of bone.
4. Discussion
The current prospective study demonstrates that post-
neoadjuvant treatment FDG-PET evaluations in adult
patients with bone sarcomas identiﬁed histopathological
treatment responders accurately when a prospective cut-oﬀ
of ≥60% reductions in SUVmax was applied.
The inability of changes in tumor size to distinguish
treatment responders from nonresponders is not surprising
and has been well established in bone sarcomas and various
types of cancers [16]. Parameters assessed by conventional
radiography such as tumor location, tumor size, radio-
graphic appearance, margination, cortical destruction, and
periosteal reaction are of limited use in assessing therapeutic
responses [17].
As a prerequisite for monitoring of treatment eﬀects
mostbonesarcomasexhibitmarkedlyincreasedFDG-uptake
with a mean baseline SUVmax of 8.1 ± 4.1g/mL (range,
3.6 to 15.7g/mL). This observation is in concordance with
two previsously published papers that describe mean SUVs
of 9.6 and 7.9, respectively [3, 18]. Thus, it should be
feasible to determine changes in FDG uptake in response
to treatment and to use this information for predicting
treatment responses. This has been reported in some earlier
prospectiveandretrospectivestudies[7,18–22].Schulteetal.
[7]observedin27patientswithosteosarcomathatadecrease
in FDG SUV tumor to background ratio from baseline to
end of treatment by at least 60% detected histopathologic
response with a sensitivity of 100% and a speciﬁcity of 80%.
In the current study we prospectively applied this
previously reported threshold as a response criterion. A 60%
threshold for a metabolic response correctly classiﬁed 7 of
8 histopathologic nonresponders as metabolic nonresponder
(speciﬁcity, 88%) and 3 of 4 histopathological responders
as metabolic responders (sensitivity, 75%). The single “false
negative” response by PET occurred in the patient withSarcoma 5
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Figure 4: FDG-PET/CT at baseline, early followup, and after completion of neoadjuvant treatments in a histopathological responder (a)
and a nonresponder (b).
Table 2: Correlation between histopathologic and metabolic response (≥60% decreases in SUVmax).
Histopathology
Metabolic response Responder
(≥90% necrosis)
Nonresponder
(<90% necrosis)
Responder (≥60%
decrease in SUVmax) 31 Positive predictive value
3/4 = 75%
Nonresponder (<60%
decrease in SUVmax) 17 Negative predictive value
7/8 = 88%
Sensitivity 3/4 = 75% Speciﬁcity 7/8 = 88% Accuracy 10/12 = 83%
the lowest baseline tumor FDG uptake of all study par-
ticipants (SUVmax at baseline: 3.6g/mL). In this patient
SUVmax decreased from baseline to late followup by only
38%, to 2.3g/mL. This false negative result is consistent with
the notion that response assessments by FDG-PET are less
reliable in tumors with lower FDG baseline uptake [23].
In a subgroup analysis that excluded patients with
chondrosarcoma and giant cell tumor the sensitivity of
FDG-PETinassessinghistopathologicresponsewasidentical
(sensitivity, 75%). However, excluding patients with those
subtypes resulted in a decreased speciﬁcity (80% versus 88%
resp.).
In a retrospective analysis of 36 patients with Ewing
sarcoma family of tumors, Hawkins et al. [18] found that a
decrease in SUV ≥50% and an end of treatment SUVmax
of <2.5g/mL detected histopathologic response with a sensi-
tivity of 83% and 76%, respectively. Despite the superiority
of changes in SUV in the detection of histopathologic
responses,anendoftreatmentSUVoflessthan2.5g/mLwas
more predictive of progression free survival in their study.
We therefore tested whether an end of treatment tumor
SUVmax of <2.5 could also identify treatment responders.
This resulted in a sensitivity of 75% and a speciﬁcity of 88%
for predicting tissue responses. However, the combination6 Sarcoma
of both response criteria (response: ≥60% decrease in
SUVmax or SUVmax at late followup <2.5; nonresponse:
<60% decreases in SUVmax and SUVmax at late followup
>2.5) correctly identiﬁed all histopathological responder
as metabolic responder (sensitivity, 100%) and 6 of 8
histopathologic nonresponder as metabolic nonresponder
(speciﬁcity, 75%).
End of treatment evaluations has limited impact on
patient management. We have previously shown that reduc-
tions in SUVmax by ≥35% after the initial cycle of neoad-
juvant treatment predicts histopathological responses in soft
tissue [5] sarcomas. In another prospective study at our
institution such early response assessments were obtained
in 4 patients with bone sarcomas. A metabolic response of
35% correctly classiﬁed 1 of 1 histopathologic responder as
metabolic responder and 2 of 3 histopathologic nonrespon-
ders as metabolic nonresponders (Figure 4). Future studies
need to determine whether such early response predictions
hold up in larger patient populations.
PET data can be analyzed semiquantitatively. This allows
for a reliable deﬁnition of metabolic tumor activity before,
during, and after neoadjuvant therapy. However, few studies
have attempted to apply response criteria across institutions
and study populations. The current study adds to a growing
body of evidence established in sarcoma and other cancers
that late reductions in SUV by ≥60% can accurately predict
responses to neoadjuvant therapy [7, 8, 24, 25].
Besides the evaluation of response/nonresponse by PET,
new imaging modalities such as dynamic magnet resonance
imaging [26] and new image analysis methods/response
criteria [27] are currently under investigation for early
response assessments in sarcoma patients. Previously pub-
lished data suggest that a combination of changes in tumor
density (>15% change) and in modiﬁed tumor size (>10%)
accurately detects early response in gastrointestinal stromal
tumors (GIST) to Imatinib treatment [27]. Whether these
imagingmodalitiesorresponsecriteriaaresuperioroverPET
and the proposed deﬁnition of a metabolic response needs to
be addressed in future studies.
The primary limitation of this study is the small study
population. However, we felt that reporting this trial adds to
growing body of literature that addresses the ability of FDG-
PET/(CT) for monitoring treatment responses in sarcoma
patients. Larger prospective studies are needed to conﬁrm
these data. Another limitation was the heterogeneity of
the study population with regards to tumor histology and
treatment regimens. However, we believe that any useful
imaging test used for monitoring therapeutic interventions
needs to be applied across disease subtypes and treatment
approaches.
In conclusion, serial FDG-PET imaging accurately clas-
siﬁed histopathologic response/nonresponse to neoadjuvant
therapy in adult primary bone sarcomas. It is noteworthy
that a combination of previously applied response criteria
(reductionsinSUVmaxby ≥60%andaposttreatmenttumor
SUVmax of <2.5) provided the best response predictions.
This information could now be applied prospectively to
examine whether PET-guided therapeutic decisions aﬀect
survival of bone sarcoma patients.
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